Concenter BioPharma Overview
Concenter BioPharma develops drugs for treating and preventing type 2 diabetes. The company has developed a family of nonsteroidal chemical complexes made from components approved for clinical use. These new chemical entities constitute a protected platform of drugs with proven efficacy and safety. The members of the platform act as potent anti-inflammatory agents, strong iron-chelating agents, and antibiotic agents. These modes of action jointly assist in treating the causes and/or symptoms of multiple indications. Concenter BioPharma is a subsidiary of Silkim Pharma.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
סטארטאפ ישראלי מפתח תרופה לסוכרת סוג 2
Israeli biotech company Concenter BioPharma is developing a drug that could potentially cure type 2 diabetes. The company has begun raising funds for clinical trials and expects the drug to be on the market within three years. Concenter BioPharma is currently nearing the end of a funding round of 4 million shekels on the Pipelbiz crowd investing platform to finance clinical trials at the end of 2020. The FDA has approved a shortened regulatory process for the drugs approval, which is expected to reach the market within three years.
Investment
growth-positive
Finally, a pill that could fix the root cause of diabetes
Concenter BioPharma, an Israeli company, is developing a drug called Zygosid-50 that aims to restore near-normal cellular sensitivity to insulin in type 2 diabetes patients. The drug has shown promising results in animal trials, reducing insulin resistance and normalizing diabetes-associated parameters. Concenter BioPharma is raising funds for clinical trials approved by the FDA and plans to conduct phase 1 and phase 2a trials in Israel. The company is self-funded but will launch a $5 million funding round for its activities in 2020. Diabetes affects a large number of people globally, and the estimated cost of treating diabetes per year is over $850 billion. Concenter BioPharma aims to develop a drug that treats insulin resistance without side effects.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $3.18M |
| Last funding | $1.18M |
| Stage | A |
| Rounds | 2 |
| Investors | 1 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | www.concenterbiopharma.com |
Locations
Israel
Photos & Videos
2 item(s)
